Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387026144> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4387026144 endingPage "AB218" @default.
- W4387026144 startingPage "AB218" @default.
- W4387026144 abstract "Background: Long-term efficacy with 48 weeks of abrocitinib treatment has been demonstrated to be comparable to efficacy at week 12 in patients with moderate-to-severe atopic dermatitis (AD). These analyses include abrocitinib-treated patients from JADE MONO-1, JADE MONO-2, JADE COMPARE, JADE TEEN, and JADE DARE who subsequently enrolled into the phase 3 long-term extension study JADE EXTEND (NCT03422822). Efficacy was assessed in subgroups of patients who achieved or did not achieve efficacy endpoints at week 12 of the parent study. Data cutoff: September 25, 2021. Among patients who achieved week 12 efficacy endpoints, the proportion with response at week 96 was 89.8% (228/254) and 85.3% (168/197) for 2:75% improvement in Eczema Area and Severity Index (EASI-75) in the 200-mg and 100-mg arms, respectively, 70.1% (122/174) and 62.4% (78/125) for Investigator’s Global Assessment clear/almost clear (IGA-0/1), and 80.1% (165/206) and 75.5% (108/143) for 2:4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) (as observed). Among patients without response to abrocitinib at week 12, the proportion with response at week 24 was 54.4% (98/180) and 50.5% (103/204) for EASI-75 in the abrocitinib 200-mg and 100-mg arms, respectively, 29.2% (107/366) and 26.9% (82/305) for IGA-0/1, and 41.0% (96/234) and 35.0% (72/206) for PP-NRS4 (as observed). Most abrocitinib-treated patients who met efficacy response criteria at week 12 were observed to have long- term efficacy at week 96. Substantial proportions of patients who do not meet response criteria at week 12 can subsequently achieve response by week 24 with further treatment." @default.
- W4387026144 created "2023-09-26" @default.
- W4387026144 creator A5000572878 @default.
- W4387026144 creator A5008286260 @default.
- W4387026144 creator A5011739266 @default.
- W4387026144 creator A5013549423 @default.
- W4387026144 creator A5014312724 @default.
- W4387026144 creator A5028077261 @default.
- W4387026144 creator A5053447705 @default.
- W4387026144 creator A5074778060 @default.
- W4387026144 creator A5079817988 @default.
- W4387026144 creator A5081892653 @default.
- W4387026144 date "2023-09-01" @default.
- W4387026144 modified "2023-09-26" @default.
- W4387026144 title "44095 Response to Abrocitinib up to Week 96 According to Short-Term Response: A Post Hoc Analysis of the JADE-EXTEND Phase 3 Trial" @default.
- W4387026144 doi "https://doi.org/10.1016/j.jaad.2023.07.874" @default.
- W4387026144 hasPublicationYear "2023" @default.
- W4387026144 type Work @default.
- W4387026144 citedByCount "0" @default.
- W4387026144 crossrefType "journal-article" @default.
- W4387026144 hasAuthorship W4387026144A5000572878 @default.
- W4387026144 hasAuthorship W4387026144A5008286260 @default.
- W4387026144 hasAuthorship W4387026144A5011739266 @default.
- W4387026144 hasAuthorship W4387026144A5013549423 @default.
- W4387026144 hasAuthorship W4387026144A5014312724 @default.
- W4387026144 hasAuthorship W4387026144A5028077261 @default.
- W4387026144 hasAuthorship W4387026144A5053447705 @default.
- W4387026144 hasAuthorship W4387026144A5074778060 @default.
- W4387026144 hasAuthorship W4387026144A5079817988 @default.
- W4387026144 hasAuthorship W4387026144A5081892653 @default.
- W4387026144 hasConcept C109214941 @default.
- W4387026144 hasConcept C121332964 @default.
- W4387026144 hasConcept C126322002 @default.
- W4387026144 hasConcept C16005928 @default.
- W4387026144 hasConcept C203092338 @default.
- W4387026144 hasConcept C2778329239 @default.
- W4387026144 hasConcept C2780032874 @default.
- W4387026144 hasConcept C2992886853 @default.
- W4387026144 hasConcept C535046627 @default.
- W4387026144 hasConcept C67761136 @default.
- W4387026144 hasConcept C71924100 @default.
- W4387026144 hasConcept C90924648 @default.
- W4387026144 hasConceptScore W4387026144C109214941 @default.
- W4387026144 hasConceptScore W4387026144C121332964 @default.
- W4387026144 hasConceptScore W4387026144C126322002 @default.
- W4387026144 hasConceptScore W4387026144C16005928 @default.
- W4387026144 hasConceptScore W4387026144C203092338 @default.
- W4387026144 hasConceptScore W4387026144C2778329239 @default.
- W4387026144 hasConceptScore W4387026144C2780032874 @default.
- W4387026144 hasConceptScore W4387026144C2992886853 @default.
- W4387026144 hasConceptScore W4387026144C535046627 @default.
- W4387026144 hasConceptScore W4387026144C67761136 @default.
- W4387026144 hasConceptScore W4387026144C71924100 @default.
- W4387026144 hasConceptScore W4387026144C90924648 @default.
- W4387026144 hasIssue "3" @default.
- W4387026144 hasLocation W43870261441 @default.
- W4387026144 hasOpenAccess W4387026144 @default.
- W4387026144 hasPrimaryLocation W43870261441 @default.
- W4387026144 hasRelatedWork W2319724149 @default.
- W4387026144 hasRelatedWork W2944298405 @default.
- W4387026144 hasRelatedWork W2968206075 @default.
- W4387026144 hasRelatedWork W3084859948 @default.
- W4387026144 hasRelatedWork W3097527510 @default.
- W4387026144 hasRelatedWork W4210693756 @default.
- W4387026144 hasRelatedWork W4236175319 @default.
- W4387026144 hasRelatedWork W4244959540 @default.
- W4387026144 hasRelatedWork W4248164545 @default.
- W4387026144 hasRelatedWork W4318579187 @default.
- W4387026144 hasVolume "89" @default.
- W4387026144 isParatext "false" @default.
- W4387026144 isRetracted "false" @default.
- W4387026144 workType "article" @default.